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Abstract: Background: Prostate cancer is one of the most frequently diagnosed neoplastic disease and the second 
leading cause of cancer mortality in men of the Western world. Despite improved methods for early detection, a large 
proportion of patients succumb to metastatic prostate cancer that is resistant to conventional therapies. The 
development of novel effective strategies to prevent and treat prostate cancer relies considerably upon increasing our 
knowledge of the interplay among various molecular and genetic alterations that lead to onset and progression of 
prostate cancer. To date, germline mutations in the cancer susceptibility gene BRCA2 represent one of the strongest risk 
factor to develop prostate cancer.  
Objective: Goal of this review is to summarize current reports investigating the presence of BRCA2 mutations in prostate 
cancer. 
Design: A comprehensive analysis of the literature on BRCA2 mutations in prostate cancer. Data source: Pubmed. 
Terms included in the search: "BRCA2 mutations", "prostate cancer". 
Results: A total of 18 studies were included in the review. The studies focused on the clinical implications of BRCA2 
mutations in prostate cancer. The findings indicate that inherited pathogenic mutations in BRCA2 predispose to highly 
aggressive prostate cancers and poor survival. Very recent reports also suggest that metastatic castration-resistant 
prostate cancers are "enriched" of BRCA2 mutations compared to the primary tumors. 
Conclusion: Because BRCA2-mutated tumors are very sensitive to PARP-inhibitors'-based chemotherapy, BRCA2 
genomic testing of patients with advanced metastatic prostate disease may enable an effective, personalized, 
therapeutic strategy. 
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INTRODUCTION 
Prostate cancer is a leading cause of morbidity and 
mortality among men in the Western world. The 
American Cancer Society estimates that in the United 
States about 220,800 new cases of prostate cancer will 
be diagnosed in 2015 and about 27,500 deaths from 
prostate cancer will occur in the same year. 
Approximately 1 man in 7 will be diagnosed with 
prostate cancer during his life. Despite improved 
methods for early detection, a large proportion of 
patients succumb to disseminated metastatic prostate 
cancer that is resistant to conventional therapies [1]. 
Therapeutic approaches involve androgen ablation, 
which prevents androgen-dependent cancer cell growth 
by predisposing cancer cells to enter an apoptotic 
pathway [2]. However, tumor clones that evade 
apoptotic death and thrive in absence of androgens 
(castration-resistant prostate cancer) normally arise 
after a few years [1]. Furthermore, the biological events 
resulting in castration-resistant prostate cancer also 
reduce the effectiveness of conventional 
chemotherapeutic agents, at least partly explained by 
the fact that apoptosis, the predominant form of cell  
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death triggered by many chemotherapeutic agents, is 
impaired in the advanced disease [1, 2].  
Age, lifestyle and genetic factors have been 
implicated in the development of prostate cancer. In 
addition, the inherited genetic background may confer 
an increased risk to develop prostate carcinoma. 
Several studies have identified recurrent somatic 
mutations or copy number alterations in oncogenes 
and/or in tumor suppressor genes in primary prostate 
cancer specimens [3]. Among these, point mutations in 
TP53, SPOP, FOXA1 and MED12 have been detected 
in a high proportion of primary prostate cancer [4]. 
Mutations in TP53 and androgen receptor (AR) are 
further enriched in metastatic, castration-resistant 
prostate cancer compared to primary prostate cancer 
[3]. New genomic alterations have been recently 
identified in PIK3CA/B, BRAF/RAF1, APC, and β-
catenin [3]. Among the inherited genetic factors, there 
is strong evidence that mutations in the Breast Cancer 
Susceptibility gene 2 (BRCA2) confer the highest risk 
to develop prostate cancer (8.6-fold in men below the 
age of 65 years) [5]. The risk of BRCA2-mutation 
carriers to develop prostate cancer at an early age (< 
56 years) is even higher (about 23-fold compared to 
non-carrier) [6].  
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Together with BRCA1, the tumor suppressor gene 
BRCA2 is among the best-known cancer-susceptibility 
genes. Germline presence of a single mutated copy of 
BRCA2 is associated with increased susceptibility to 
breast and ovarian cancer in women and prostate 
cancer in men [7]. Although several different genes 
have been implicated in the development of prostate 
cancer, very few confer a risk as high as mutations in 
BRCA2 [8]. Somatic inactivation of the wild-type copy 
of the BRCA2 gene is always required to support 
tumorigenesis in BRCA2 mutant carriers [9]. The tumor 
suppressor BRCA2 is a caretaker protein that plays an 
important role in repairing DNA double-strand breaks 
(DSBs) through the homologous recombination (HR) 
process by regulating the activity of the recombinase 
Rad51 [10]. Thus, cells deficient of functional BRCA2 
would use alternative, error-prone mechanisms to 
repair DSBs, potentially resulting in genomic instability 
that may underlie the increased susceptibility to 
develop cancer in BRCA2 mutation carriers [11]. In 
addition, BRCA2 has been implicated in the regulation 
of transcription, proliferation, cell cycle control and cell 
invasion [12, 13]. These studies suggest that BRCA2 
may control a diverse range of cellular processes, 
besides its well-recognized role in DNA recombination 
and repair processes, and that its loss may contribute 
to prostate cancer development and progression 
through multiple mechanisms, including increased 
genome instability, cell proliferation and metastatic 
potential. In agreement with these findings, Francis et 
al. [14] have found that specific deletion of Brca2 in 
murine prostate epithelial cells causes hyperplasia and 
low-grade prostatic intra-epithelial neoplasia (PIN). In 
addition, simultaneous deletion of Brca2 and Trp53 in 
these cells lead to high-grade PIN, further confirming 
that BRCA2 acts as a tumor suppressor in prostate 
epithelial cells. 
Aim of this study is to summarize current literature 
reporting mutations of BRCA2 in primary and in 
metastatic, castration-resistant prostate cancer as well 
as their correlation with patients' clinical outcome. 
METHODS 
A comprehensive search of Pubmed was 
performed. The keywords: "prostate cancer" and 
"BRCA2 mutations" were used to identify the relevant 
literature from 2003 to 2015. A total of 177 potentially 
relevant manuscripts were retrieved. After removal of 
single case-report studies and articles citing the term 
"prostate" but not effectively including prostate cancer 
specimens, 18 manuscripts were included in this 
literature review (Figure 1; Table 1). 
RESULTS AND DISCUSSION 
One of the first large-scale study investigating the 
potential relation between occurrence of BRCA2 
mutations and prostate cancer development is dated 
2003. Edwards et al. [6] sequenced the BRCA2 coding 
region for germline mutations in the lymphocytes of 263 
men diagnosed with prostate cancer at an early age (< 
55 years old). Deleterious protein-truncating mutations 
were detected in 2.3% men (6 patients), and 22 
BRCA2 variants of uncertain significance were also 
found. Overall, the relative risk of early-onset prostate 
cancer in BRCA2-mutation carriers was 23-fold.  
 
Figure 1: Flow diagram of the criteria used for the studies selected in this review. 
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Table 1: Characteristics of the Included Studies 
Study # Samples Study Design Results 
Edwards et al.  
2003 [6] 
263 men diagnosed with 
prostate cancer at an early age 
(≤ 55 years old) 
The complete BRCA2 coding 
region was sequenced in 
lymphocytes collected from 
patients 
2.3% men displayed deleterious protein-
truncating BRCA2 mutations; 22 BRCA2 variants 
of uncertain significance were identified.  
The relative risk of early-onset prostate cancer in 
BRCA2-mutation carriers was 23-fold. 
Tryggvadottir et al. 
2007 [15] 
527 prostate cancer patients  Prevalence of the BRCA2 
999del 5 founder mutation was 
assessed in prostate cancer 
patients belonging to the 
Icelandic population 
5.7% of the patients carried the BRCA2 999del 5 
mutation. 
The mutation conferred lower mean age at 
diagnosis, higher tumor grade, more advanced 
tumor stage and reduced median survival. 
Mitra et al.  
2008 [16] 
16 BRCA2 mutation carriers and 
20 controls affected by prostate 
cancer 
Archived histopathological 
tissue sections of BRCA2 
mutation carriers were 
collected, reviewed and 
compared to age-matched 
controls 
BRCA2 mutations conferred higher Gleason 
grade (8-10). 
Agalliu et al.  
2009 [17] 
979 prostate cancer cases and 
1.251controls among Ashkenazi 
Jewish men 
Biological samples were 
screened for the BRCA1 
185delAG, BRCA1 5382insC 
and the BRCA2 6174delT 
founder mutations  
Prostate cancer risk was increased (odd ratios: 
1.9) for BRCA2 mutation carriers but not for 
BRCA1 mutation carriers. 
BRCA2 founder mutation conferred a 3-fold 
elevated risk of high-grade prostate cancer.  
Gallagher et al. 
2010 [18] 
832 prostate cancer cases in the 
Ashkenazi Jewish population 
Prevalence of the BRCA2 
6174delT mutation was 
assessed in prostate cancer 
patients from the Ashkenazi 
Jewish population. Clinical 
outcome was compared 
26/832 patients were BRCA2 6174delT mutation 
carriers.  
BRCA2 mutation was associated with a 3-fold 
risk of prostate cancer and higher histological 
grade. 
Narod et al.  
2008 [19] 
182 prostate cancer patients 
with a BRCA2 mutation and 119 
prostate cancer patients with a 
BRCA1 mutation 
Survival between BRCA2 and 
BRCA1 mutation carriers was 
compared 
The median survival from diagnosis was 4 years 
for patients with a BRCA2 mutation and 8 years 
for patients with a BRCA1 mutation. 
Edwards et al.  
2010 [20] 
21 prostate cancer patients with 
a BRCA2 mutation and 1587 
controls 
Clinical outcome was 
compared 
The median survival from diagnosis was 4.8 
years for patients with a BRCA2 mutation and 
8.5 years for control patients. 
Loss of heterozygosity was found in most of the 
tumors from BRCA2 mutation carriers. 
Willems et al. 
 2008 [21] 
14 prostate cancer patients with 
a BRCA2 mutation  
Loss of heterozigosity at the 
BRCA2 gene was examined  
10/14 tumors exhibited loss of heterozigosity at 
the BRCA2 gene. 
Thorne et al.  
2011 [22] 
148 men with prostate cancer 
from 1.423 families with a history 
of breast cancer were analyzed 
from the kConFab consortium 
Presence of BRCA2 mutations 
and pathological/clinical 
outcome were analyzed 
40/148 men showed BRCA2 mutations. 
77.5% of BRCA2 mutation carriers and 58.7% of 
noncarriers had high-risk disease: BRCA2 
mutation carriers had higher Gleason grade and 
more locally advanced disease than the 
noncarriers. 
Mitra et al.  
2011 [23] 
300 prostate cancer cases: 205 
BRCA1 (89) or BRCA2 (116) 
mutation carriers, 95 controls 
PSA levels were monitored The positive predictive value of PSA screening 
was 47.6% for potentially aggressive prostate 
cancer in BRCA2 mutation carriers. 
Akbari et al.  
2014 [24] 
4.187 prostate cancer men BRCA2 gene was sequenced 
in its entirety and clinical 
outcome was assessed 
12-year prostate-cancer specific survival rate 
was 94.3% for non-carriers and 61.8% for 
BRCA2-mutation carriers. 
Maier et al. 
 2014 [25] 
382 familial and 92 sporadic 
prostate cancer cases with 
early-onset (≤ 60 years old) 
All BRCA2 exons were 
sequenced 
5 BRCA2 pathogenic mutations were detected in 
familial cases of prostate cancer. 10 BRCA2 
variants of uncertain significance were detected 
in BRCA2 carriers and noncarriers groups.  
Carriers of the 5 BRCA2 pathogenic mutations 
had increased PSA levels at diagnosis, 
aggressive disease and reduced survival 
compared to noncarriers. 
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(Table 1). Contd ….. 
Study # Samples Study Design Results 
Kote-Jarai et al. 
2011 [5] 
1.864 prostate cancer patients BRCA2 gene was sequenced 19 protein-truncating mutations, 3 in-frame 
deletions and 69 missense variants of uncertain 
significance were identified. The 19 protein-
truncating mutations were all present in younger 
onset cases with age at diagnosis < 65 years 
Castro et al.  
2013 [26] 
2.019 prostate cancer cases: 
61 BRCA2 mutation carriers, 
18 BRCA1 mutation carriers, 
and 1940 noncarriers 
Tumor features and clinical 
outcomes were analyzed 
BRCA2 mutations predisposed to an aggressive 
prostate cancer phenotype. Nodal involvement 
and distant metastasis were more common in 
BRCA2 mutation carriers than in noncarriers. 
Castro et al.  
2015 [27] 
1.302 cases of local/locally 
advanced prostate cancer (67 
BRCA2 carriers and 1.235 
noncarriers) 
Tumor features and clinical 
outcomes were analyzed 
At 10 years after treatment, 84% of noncarriers 
and 50% of carriers were free of metastasis. 
Multivariate analysis confirmed that BRCA2 
mutation status was an independent prognostic 
factor for metastasis-free survival. 
Arbini et al.  
2011 [28] 
80 cases of sporadic prostate 
cancer 
BRCA2 protein levels were 
analyzed by 
immunohistochemistry in 
prostate cancer and adjacent 
normal prostate tissue 
Significant reduction of BRCA2 protein in about 
70% of sporadic prostate cancer cases. 
Beltran et al.  
2013 [30] 
45 cases of sporadic prostate 
cancer: 16 localized, 4 
metastatic hormone-naive, 
and 25 metastatic castration-
resistant prostate cancers 
DNA alterations in several genes 
were analyzed by sequencing 
Homozygous BRCA2 deletions were detected in 
1 out of 4 metastatic hormone-naive cancers and 
3 out of 25 metastatic castration-resistant 
prostate carcinomas. Clinically localized prostate 
cancers did not show BRCA2 alterations, 
besides one primary tumor from a patient known 
to have later developed metastatic castration-
resistant disease. 
Robinson et al. 
2015 [3] 
150 metastatic castration-
resistant sporadic prostate 
cancers 
Whole-exome and transcriptome 
sequencing of bone or soft 
tissue tumor biopsies from 
prostate cancer patients 
Aberrations of BRCA2 detected at substantially 
higher frequency in the metastatic lesions (13%) 
compared to primary prostate cancers (5%). 
 
More recent studies have associated the presence 
of deleterious germline mutations in BRCA2 with a 
more aggressive phenotype, nodal involvement and 
poor survival in prostate cancer patients. Tryggvadottir 
et al. [15] analyzed occurrence of the BRCA2 999del5 
mutation in prostate cancer patients. This mutation, 
which occurs in exon 9 of the BRCA2 gene, is present 
in 6-7% of breast cancer patients in the Icelandic 
population. The authors assessed the potential 
association between BRCA2 999del5 mutation and 
progression of prostate carcinoma in 527 patients 
diagnosed with prostate cancer. The mutation, which 
was carried by 5.7% of the patients (30/527), conferred 
a lower mean age at diagnosis (69 years compared to 
74 years of non-carriers), higher tumor grade (84% of 
carriers with Gleason grade 3-4 compared to 52.7% of 
non-carriers), more advanced tumor stage (T3 or T4 in 
carriers: 79.3% compared to 38.6% of non-carriers), 
and reduced median survival (2.1 ÷ 3.6 years in 
carriers and 12.4 ÷ 19.7 years in non-carriers), 
indicating that the Icelandic BRCA2 999del5 founder 
mutation is strongly correlated with a rapidly 
progressing lethal disease. The results of this study 
were consistent with a subsequent study performed in 
UK on 16 BRCA2 mutation carriers and a control group 
[16] showing higher Gleason grade in BRCA2 mutation 
carriers. Similar results were obtained by Agalliu et al. 
[17] on Ashkenazi Jewish men which carry the BRCA2 
6174delT founder mutation. The study was conducted 
on 979 prostate cancer cases and 1.251 controls. 
Overall, BRCA2 mutation carriers had an increased risk 
to develop high-grade prostate cancer with a poorly 
differentiated phenotype. Gallagher et al. [18] 
confirmed the clinical impact of the same BRCA2 
founder mutation, 6174delT, in Ashkenazi Jewish men: 
out of 832 men diagnosed with prostate cancer, 26 
displayed the mutation which was associated with a 
poorly differentiated phenotype. 
Narod et al. [19] compared survival of 182 prostate 
cancer patients with a BRCA2 mutation with that of 119 
prostate cancer patients with a mutation in the tumor 
suppressor gene BRCA1 and found that the median 
survival from diagnosis was significantly reduced in the 
BRCA2 mutation carriers (4 years versus 8 years of 
BRCA1 mutation carriers). Poorer survival of prostate 
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cancer patients with a BRCA2 germline mutation was 
also observed by other two subsequent studies. 
Edwards et al. [20] performed an analysis on 21 
BRCA2-mutation carriers and matched controls, and 
found that median survival of BRCA2 mutation carriers 
was 4.8 years versus 8.5 years of the control. In 
addition, out of 5 prostate tissue specimens available 
from BRCA2-mutation carriers, 33 exhibited loss of 
heterozigosity (LOH) of the wild-type BRCA2 allele, 
consistent with a tumor suppressor model for BRCA2. 
LOH at the BRCA2 locus was also previously reported 
in 10 out of 14 prostate tissue specimens from BRCA2-
mutation carriers [21]. Thorne et al. [22] confirmed 
significantly elevated risk of high-grade cancer in 
prostate cancer patients which carried a BRCA2 
mutations. In this study, a total of 148 men from 1.423 
families with a history of breast cancer were analyzed 
from the kConFab consortium (Australia). Each 
participant had a verified case of prostate cancer and 
was confirmed as carrier or non carrier of a BRCA2 
pathogenic mutation. The results of this study show 
that 77.5% of BRCA2 mutation carriers and 58.7% of 
non carriers control displayed high-risk disease.  
In 2011, the first multicentre prostate cancer large 
screening study targeted at men with mutations to 
BRCA1 or BRCA2 (IMPACT project) was published 
[23]. In total, 300 subjects from 20 different medical 
centers were recruited over a period of 33 months: 205 
were carriers of either BRCA1 or BRCA2 mutations (89 
BRCA1 and 116 BRCA2) and 95 were controls (no 
BRCA mutations). In this first screening, prostate-
specific antigen (PSA) levels were reported as a more 
accurate predictor of potentially aggressive prostate 
cancer in BRCA-mutation carriers than in the general 
population. This study has been followed by other 
large-scale studies. In a 2014's report from Narod's 
group and collaborators [24], 4187 men who underwent 
prostate cancer biopsy between 1998 and 2010 were 
screened for mutations of the BRCA2 gene in its 
entirety and the patients were followed for survival from 
prostate cancer until December 2012: the 12-year 
prostate-cancer specific survival rate 94.3% for non-
carriers and 61.8% for BRCA2-mutation carriers. All 
exons of BRCA2 were also sequenced by Maier et al. 
[25] in a German set of 382 familial prostate cancer 
cases and 92 sporadic cancer cases with early onset of 
the neoplastic disease (< 60 years). Five BRCA2 
pathogenic mutations and ten BRCA2 variants of 
uncertain significance were detected. While the first 
were specifically detected in patients with a familial 
history of prostate cancer, the 10 variants were present 
in both groups of patients. Carriers of the five 
pathogenic mutations had increased PSA levels at 
diagnosis, aggressive disease and reduced survival 
compared to noncarriers.  
Three recent studies from Dr. Eeles' group [5, 26, 
27] have provided more insights into the clinical 
implications of deleterious mutations in the BRCA2 
gene. In the first study [5], 1.864 patients with prostate 
cancer recruited from the UK Genetic Prostate Cancer 
Study were screened, and 19 protein-truncating 
mutations (16 frameshift and 3 nonsense mutations) all 
present in younger onset cases with age at diagnosis < 
65 years were identified, further confirming that 
deleterious BRCA2 mutations predispose to young-
onset prostate cancer (8.6-fold increased risk of 
prostate cancer by age 65). In the next study, the 
prostate tumor features and outcomes of 2.019 patients 
with prostate cancer, of which 61 BRCA2 carriers, 18 
BRCA1 carriers, and 1.940 noncarriers, were analyzed. 
The analysis confirmed that BRCA2 mutations 
predispose to an aggressive prostate cancer 
phenotype, with nodal involvement and distant 
metastasis more common in BRCA2 mutation carriers 
than in noncarriers. In addition, the study confirmed 
that mutation carriers diagnosed with local prostate 
carcinoma developed metastasis earlier than 
noncarriers and had worse survival outcome [26]. 
Finally, in a study published in 2015, tumor features 
and outcomes of 1.302 patients (67 BRCA2 carriers 
and 1.235 noncarriers) with locally advanced prostate 
cancer were analyzed [27]. At 10 years after treatment, 
84% of noncarriers and 50% of carriers were free of 
metastasis. Multivariate analysis confirmed that BRCA2 
mutation status was an independent prognostic factor 
for metastasis-free survival. All these studies 
demonstrate that inherited BRCA2 pathogenic 
mutations predispose to highly aggressive, metastatic 
prostate cancer. The molecular basis for the 
aggressive behavior of the BRCA2-associated prostate 
carcinomas is still not clear, but it may be related to the 
increased migratory and invasive properties that exhibit 
prostate cancer cells after suppression of BRCA2 
protein levels [13]. 
All the above described studies have been 
performed in BRCA2-mutation carriers, and clinical 
histopathological features of the tumors as well as 
studies of LOH at the BRCA2 locus have been reported 
by analyzing primary prostate tumors. The potential 
role of BRCA2 in sporadic prostate cancers, which 
represent the vast majority of prostate carcinomas, is 
still under investigation. Indeed, though deleterious 
26    World Journal of Oncology Research, 2015, Vol. 2 Arbini and Moro 
BRCA2 mutations are rare in sporadic prostate cancer 
patients (BRCA noncarrier patients), a recent study, 
which included 80 sporadic prostate cancer specimens 
and the adjacent normal tissue, reported that a 
significant percentage of prostate cancer tissues (about 
70%) had decreased BRCA2 protein levels [28], 
suggesting that at least a group of sporadic prostate 
cancers may develop "BRCAness" clinical 
characteristics. This latter study included analysis of 
BRCA2 protein levels but not a BRCA2-mutational 
analysis of the patients. However, despite the fact that 
BRCA2 mutations are rare in sporadic cancers, it 
should be noted that reduction of BRCA2 protein in 
prostate cancer tissues may be ascribed to 
mechanisms different than mutations, including post-
translational regulation [28, 29]. In addition, a recent 
study has shown that about 12% of advanced, highly 
aggressive sporadic prostate carcinomas display 
genomic alterations leading to genetic deletion of 
BRCA2 [30]. This study analyzed the DNA alterations 
in 45 prostate tumors representing the various stages 
of progression of the disease: 16 localized prostate 
cancers, 4 metastatic hormone-naive prostate cancers, 
25 metastatic castration-resistant prostate carcinomas. 
Interestingly, homozygous BRCA2 deletions were 
detected in 1 out of 4 metastatic hormone-naive 
cancers and 3 out of 25 metastatic castration-resistant 
prostate carcinomas. Clinically localized prostate 
cancers did not show BRCA2 alterations, besides one 
primary tumor from a patient known to have later 
developed metastatic castration-resistant disease. 
These results suggest that BRCA2 gene deletions, 
though not present in primary tumors, may be acquired 
during cancer progression, and further support a role of 
BRCA2 loss in conferring an aggressive phenotype to 
prostate cancer cells. Intriguingly, a multi-institutional 
study published a few months ago conducted whole-
exome and transcriptome sequencing of bone or soft 
tissue tumor biopsies from 150 metastatic castration-
resistant prostate cancers and found aberrations of 
BRCA2 at substantially higher frequency in the 
metastatic lesions (13%) compared to primary prostate 
cancers (5%) (3]. This finding has significant clinical 
implications because tumors with loss of BRCA2 have 
been reported to be very sensitive to PARP inhibitors, a 
new class of anticancer drugs [31]. 
CONCLUSIONS 
The development of newly effective strategies for 
prevention and therapy of prostate carcinoma relies 
heavily upon increasing our knowledge of the interplay 
among various molecular alterations that lead to onset 
and progression of prostate cancer. Germline 
mutations in BRCA2 not only increase the risk of 
developing prostate cancer but also predispose to a 
highly aggressive disease with poor outcome. A 
genomic analysis on prospective biopsies from 
sporadic, metastatic castration-resistant cancers may 
enable personalized therapies, which could include the 
PARP inhibitor olaparib, a recently FDA-approved anti-
cancer drug which acts against cancers in patients with 
hereditary BRCA mutations.  
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